These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 29848153)

  • 21. A retrospective study on drug survival of biologic among patients with psoriasis seen in tertiary hospital in Johor Malaysia.
    Mashor M; Wong KW; Tey KE; Choon SE
    Med J Malaysia; 2022 Nov; 77(6):689-695. PubMed ID: 36448386
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biological treatments for paediatric psoriasis : a retrospective observational study on biological drug survival in daily practice in childhood psoriasis.
    Phan C; Beauchet A; Burztejn AC; Severino-Freire M; Barbarot S; Girard C; Lasek A; Reguiai Z; Hadj-Rabia S; Abasq C; Brenaut E; Droitcourt C; Perrussel M; Mallet S; Phan A; Lacour JP; Khemis A; Bourrat E; Chaby G; Deborde R; Plantin P; Maruani A; Piram M; Maccari F; Fougerousse AC; Kupfer-Bessaguet I; Balguérie X; Barthelemy H; Martin L; Quiles-Tsimaratos N; Mery-Brossard L; Pallure V; Lons-Danic D; Bouilly-Auvray D; Beylot-Barry M; Puzenat E; Aubin F; Mahé E; ;
    J Eur Acad Dermatol Venereol; 2019 Oct; 33(10):1984-1992. PubMed ID: 30883928
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systemic Treatment of Recalcitrant Pediatric Psoriasis: A Case Series and Literature Review.
    Garber C; Creighton-Smith M; Sorensen EP; Dumont N; Gottlieb AB
    J Drugs Dermatol; 2015 Aug; 14(8):881-6. PubMed ID: 26267734
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose Modification in Biologic Therapy for Moderate to Severe Psoriasis: A Descriptive Analysis in a Clinical Practice Setting.
    Baniandrés O; Rodríguez-Soria VJ; Romero-Jiménez RM; Suárez R
    Actas Dermosifiliogr; 2015 Sep; 106(7):569-77. PubMed ID: 25935194
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): A retrospective observational study on biologic drug survival in daily practice.
    Vilarrasa E; Notario J; Bordas X; López-Ferrer A; Gich IJ; Puig L
    J Am Acad Dermatol; 2016 Jun; 74(6):1066-72. PubMed ID: 27004803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A retrospective observational study on biological drug treatment in a daily practice serving patients with psoriasis in Japan.
    Ohata C; Ohyama B; Nanri A; Shintani T; Nakama T
    J Dermatolog Treat; 2019 Feb; 30(1):45-48. PubMed ID: 29676591
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis.
    Carrera CG; Dapavo P; Malagoli P; Naldi L; Arancio L; Gaiani F; Egan CG; Di Mercurio M; Cattaneo A
    J Dermatolog Treat; 2018 Aug; 29(5):481-486. PubMed ID: 29058948
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.
    Mason KJ; Barker JNWN; Smith CH; Hampton PJ; Lunt M; McElhone K; Warren RB; Yiu ZZN; Griffiths CEM; Burden AD;
    JAMA Dermatol; 2018 May; 154(5):581-588. PubMed ID: 29590279
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Switching of biologics in psoriasis: Reasons and results.
    Honda H; Umezawa Y; Kikuchi S; Yanaba K; Fukuchi O; Ito T; Nobeyama Y; Asahina A; Nakagawa H
    J Dermatol; 2017 Sep; 44(9):1015-1019. PubMed ID: 28488283
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis.
    Egeberg A; Ottosen MB; Gniadecki R; Broesby-Olsen S; Dam TN; Bryld LE; Rasmussen MK; Skov L
    Br J Dermatol; 2018 Feb; 178(2):509-519. PubMed ID: 29094341
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry.
    Zweegers J; van den Reek JM; van de Kerkhof PC; Otero ME; Kuijpers AL; Koetsier MI; Arnold WP; Berends MA; Weppner-Parren L; Ossenkoppele PM; Njoo MD; Mommers JM; van Lümig PP; Driessen RJ; Kievit W; de Jong EM
    Br J Dermatol; 2016 Aug; 175(2):340-7. PubMed ID: 26989852
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of biologic therapies in psoriasis vulgaris.
    Mala R; Fida M; Jorgaqi E; Vasili E
    Dermatol Ther; 2019 Jul; 32(4):e12936. PubMed ID: 30983095
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Paradoxical onset of psoriatic arthritis during treatment with biologic agents for plaque psoriasis: a combined dermatology and rheumatology clinical study.
    Napolitano M; Balato N; Caso F; Costa L; Megna M; Cirillo T; Balato A; Scarpa R
    Clin Exp Rheumatol; 2017; 35(1):137-140. PubMed ID: 27749221
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug survival rates and reasons for drug discontinuation in psoriasis.
    Arnold T; Schaarschmidt ML; Herr R; Fischer JE; Goerdt S; Peitsch WK
    J Dtsch Dermatol Ges; 2016 Nov; 14(11):1089-1099. PubMed ID: 27879076
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patient Adherence to Biologic Agents in Psoriasis.
    Hsu DY; Gniadecki R
    Dermatology; 2016; 232(3):326-33. PubMed ID: 27093295
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
    Iskandar IYK; Warren RB; Lunt M; Mason KJ; Evans I; McElhone K; Smith CH; Reynolds NJ; Ashcroft DM; Griffiths CEM;
    J Invest Dermatol; 2018 Apr; 138(4):775-784. PubMed ID: 29080680
    [TBL] [Abstract][Full Text] [Related]  

  • 37. To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis.
    Ahn CS; Dothard EH; Garner ML; Feldman SR; Huang WW
    J Am Acad Dermatol; 2015 Sep; 73(3):420-8.e1. PubMed ID: 26184440
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Persistence of treatment with biologics for patients with psoriasis: a real-world analysis of 16 545 biologic-naïve patients from the French National Health Insurance database (SNIIRAM).
    Sbidian E; Mezzarobba M; Weill A; Coste J; Rudant J
    Br J Dermatol; 2019 Jan; 180(1):86-93. PubMed ID: 29791721
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database.
    Sruamsiri R; Iwasaki K; Tang W; Mahlich J
    BMC Dermatol; 2018 Jul; 18(1):5. PubMed ID: 29996929
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris.
    Gniadecki R; Kragballe K; Dam TN; Skov L
    Br J Dermatol; 2011 May; 164(5):1091-6. PubMed ID: 21219290
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.